Pablo Corral Shares New Insights: Genome Editing and Gene Therapy for Lipid Disorders
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A must read article
‘Gene therapy and genome editing for lipoprotein disorders‘ provides a comprehensive and timely overview of how advances in genetic medicine—including AAV gene addition, CRISPR editing, and RNA-based strategies—are reshaping the prevention and management of dyslipidaemias and ASCVD.
This open-access article highlights how innovative approaches may overcome limitations of lifelong lipid-lowering therapy, address unmet clinical needs in familial and polygenic disorders, and integrate polygenic risk scores and machine learning to personalize cardiovascular prevention.
An excellent resource for clinicians, researchers, and students interested in the rapidly evolving field of cardiovascular genetics.”
Title: Gene therapy and genome editing for lipoprotein disorders
Authors: Chen Gurevitz, Archna Bajaj, Amit V Khera, Ron Do, Heribert Schunkert, Kiran Musunuru, Robert S Rosenson
Read the full paper here.
Stay informed with Hemostasis Today.
-
Jul 9, 2026, 19:20Bradley Maron: The Beginning of a New Chapter for Circulation
-
Jul 9, 2026, 19:00Wolfgang Miesbach: ISTH 2026 Showcases the Future of Gene Therapy
-
Jul 9, 2026, 18:21Martin Vanden Eede: Can We Safely Reduce Anticoagulation During ECMO?
-
Jul 9, 2026, 18:00Dorothée Faille: Discovering Versailles During ISTH 2026
-
Jul 9, 2026, 16:45Rutbaa Ayaz Shaikh: One Step Further in Medical Research
-
Jul 9, 2026, 14:49Celebrating a Century of von Willebrand Disease Research and Care – Seminars in Thrombosis and Hemostasis
-
Jul 9, 2026, 14:38Valance Washington: International Hemostasis Community Prepares for GRC 2026
-
Jul 9, 2026, 14:27Dima Shulkin: Next-Generation AI Models Improve Early Sepsis Recognition
-
Jul 9, 2026, 14:12Omar Hajji: Seasonal Determinants of Mortality in Sepsis and Cardiogenic Shock